Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Cohn

Showing results (201-210 of 302) with videos related to

Pageof 31
Sort By:
Oncoscience|January 17, 2015
Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitorGeorgia A McCann, Shan Naidu, Kellie S Rath, et al.
International Journal of Molecular Sciences|November 20, 2019
Upgrading the Repertoire of miRNAs in Gastric Adenocarcinoma to Provide a New Resource for Biomarker DiscoveryMichelle E Pewarchuk, Mateus C Barros-Filho, Brenda C Minatel, et al.
Journal of Minimally Invasive Gynecology|January 10, 2015
Predicting inpatient stay lasting 2 midnights or longer after robotic surgery for endometrial cancerMargaret I Liang, Maggie A Rosen, Kellie S Rath, et al.
Gynecologic Oncology|April 3, 2026
Evaluation of immunotherapy response in the radiated field in patients with recurrent endometrial and cervical cancerJulia Chalif, Molly Morton, Anna Gonzalez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2020
Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor ImmunityBangxing Hong, Valerie Chapa, Uksha Saini, et al.
Gynecologic Oncology|June 5, 2024
Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84]Courtney J Riedinger, David A Barrington, Christa I Nagel, et al.
Gynecologic Oncology|October 22, 2011
Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinomaIwona Podzielinski, Marcus E Randall, Patrick J Breheny, et al.
Gynecologic Oncology|June 26, 2012
A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcomaLeigh A Cantrell, Laura Havrilesky, Dominic T Moore, et al.
Gynecologic Oncology|March 30, 2024
RETRACTED: Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancerCourtney J Riedinger, David A Barrington, Christa I Nagel, et al.
Gynecologic Oncology|December 31, 2021
Who will be readmitted? Evaluation of the laparoscopic hysterectomy readmission score in a gynecologic oncology population undergoing robotic-assisted hysterectomyMichelle D S Lightfoot, Ashley S Felix, Erin E Bishop, et al.
Pageof 31

Showing results (201-210 of 302) with videos related to

Sort By:
Pageof 31
Oncoscience|January 17, 2015
Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitorGeorgia A McCann, Shan Naidu, Kellie S Rath, et al.
International Journal of Molecular Sciences|November 20, 2019
Upgrading the Repertoire of miRNAs in Gastric Adenocarcinoma to Provide a New Resource for Biomarker DiscoveryMichelle E Pewarchuk, Mateus C Barros-Filho, Brenda C Minatel, et al.
Journal of Minimally Invasive Gynecology|January 10, 2015
Predicting inpatient stay lasting 2 midnights or longer after robotic surgery for endometrial cancerMargaret I Liang, Maggie A Rosen, Kellie S Rath, et al.
Gynecologic Oncology|April 3, 2026
Evaluation of immunotherapy response in the radiated field in patients with recurrent endometrial and cervical cancerJulia Chalif, Molly Morton, Anna Gonzalez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2020
Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor ImmunityBangxing Hong, Valerie Chapa, Uksha Saini, et al.
Gynecologic Oncology|June 5, 2024
Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84]Courtney J Riedinger, David A Barrington, Christa I Nagel, et al.
Gynecologic Oncology|October 22, 2011
Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinomaIwona Podzielinski, Marcus E Randall, Patrick J Breheny, et al.
Gynecologic Oncology|June 26, 2012
A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcomaLeigh A Cantrell, Laura Havrilesky, Dominic T Moore, et al.
Gynecologic Oncology|March 30, 2024
RETRACTED: Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancerCourtney J Riedinger, David A Barrington, Christa I Nagel, et al.
Gynecologic Oncology|December 31, 2021
Who will be readmitted? Evaluation of the laparoscopic hysterectomy readmission score in a gynecologic oncology population undergoing robotic-assisted hysterectomyMichelle D S Lightfoot, Ashley S Felix, Erin E Bishop, et al.
Pageof 31